SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
---------------
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 28, 2005
LIGAND PHARMACEUTICALS INCORPORATED
(Exact name of registrant as specified in its charter)
DELAWARE
(State or other jurisdiction of incorporation)
000-20720
(Commission File Number)
10275 SCIENCE CENTER DRIVE,
SAN DIEGO, CALIFORNIA
(Address of principal executive offices)
(858) 550-7500
(Registrant's telephone number, including area code)
77-0160744
(I.R.S. Employer Identification No.)
92121-1117
(Zip Code)
ITEM 8.01 OTHER EVENTS
On March 28, 2005, the registrant reported its Pivotal Trial results
for Front-Line Non-Small Cell Lung Cancer.
A copy of the press release issued by the registrant on March 28, 2005,
concerning the foregoing results is furnished herewith as Exhibit 99.1 and is
incorporated herein by reference.
ITEM 9.01 EXHIBITS
EXHIBIT NUMBER DESCRIPTION
-------------- -----------
99.1 Press Release of the Company dated March 28, 2005
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has caused this report to be signed on its behalf by the undersigned.
LIGAND PHARMACEUTICALS INCORPORATED
Date : March 28, 2005 By: /S/WARNER BROADDUS
Name: Warner Broaddus
Title: Vice President, General Counsel & Secretary